Samsung BioLogics to Construct World’s Largest Biopharmaceutical Manufacturing Plant

Samsung BioLogics’ US$724 million plant is set to begin operations in the fourth quarter of 2018.

AsianScientist (Dec. 30, 2015) – Samsung BioLogics has celebrated the groundbreaking of its third plant in the Incheon Free Economic Zone, Songdo, Korea. With a total investment of 850 billion won (~US$724 million), Samsung Biologics aims for the third plant to be a world-leading facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and to begin operation in the fourth quarter of 2018 after validation.

Once it begins operation, Samsung BioLogics expects to become the world’s largest biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters.

“We are investing in a third plant to provide a stable supply of biopharmaceuticals, a market which is growing exponentially, and to meet the manufacturing demands from global biopharmaceutical companies,” said Samsung BioLogics President & CEO Dr. TH Kim.

“With the world’s largest capacity and the capability to operate 365 days a year non-stop, the third plant will boast world-class quality and productivity,” he added.

Once the third plant is in full operation, Samsung BioLogics expects it will be able to reach two trillion won (~US$1.7 billion) in annual sales and 1 trillion won (~US$850 million) in operating profit. In the longer term, the company plans to continuously expand its CMO business with further investments planned for 4th and 5th plants.

Samsung BioLogics’ first plant has recently received official approval for production from the US Food and Drug Administration, and its second plant is scheduled to begin operation in early 2016, according to Samsung Biologics.


Source: Samsung BioLogics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist